Dr. Tseng is a highly regarded surgical oncologist and gastrointestinal surgeon, whose practice encompasses the upper gastrointestinal tract. She has led a group of diverse BIDMC faculty in oncology research, education and care for GI, endocrine, breast, as well as melanomas and sarcomas, and other malignancies.
Dr. Tseng has published more than 100 peer-reviewed journal articles on reducing surgical risk, cancer biomarkers and on developing models for cancer treatment sequencing strategies, with a strong focus on racial and socioeconomic disparities in care, an important BMC and BUSM mission. She has collaborated with the Massachusetts Department of Public Health to assess the impact of factors including insurance, disparities and health care reform on cancer diagnosis, treatment and prevention. She was the Founding Director of SOAR (Surgical Outcomes Analysis & Research) at UMass in 2007, a research initiative to improve treatment strategies for a broad range of surgical conditions and to develop tools to assess and reduce risk. At BIDMC, she and her co-leaders have led the continued development of SOAR as a health services and outcomes research group.
Dr. Tseng is also a dedicated educator of medical students and residents who has mentored numerous trainees throughout her research career.
- Chair, Surgery, Boston University School of Medicine
- Chief, Surgery, Boston Medical Center
- University of California, San Francisco, MD
- Harvard School of Public Health, MPH
- Stanford University, BS
- Published on 4/12/2018
van Roessel S, Kasumova GG, Tabatabaie O, Ng SC, van Rijssen LB, Verheij J, Najarian RM, van Gulik TM, Besselink MG, Busch OR, Tseng JF. Pathological Margin Clearance and Survival After Pancreaticoduodenectomy in a US and European Pancreatic Center. Ann Surg Oncol. 2018 Apr 12. PMID: 29651577.
- Published on 3/8/2018
Fadayomi AB, Kasumova GG, Tabatabaie O, de Geus SWL, Kent TS, Ng SC, Moser AJ, Callery MP, Ashley SW, Tseng JF. Unique predictors and economic burden of superficial and deep/organ space surgical site infections following pancreatectomy. HPB (Oxford). 2018 Mar 08. PMID: 29526467.
- Published on 3/8/2018
Qian ZR, Rubinson DA, Nowak JA, Morales-Oyarvide V, Dunne RF, Kozak MM, Welch MW, Brais LK, Da Silva A, Li T, Li W, Masuda A, Yang J, Shi Y, Gu M, Masugi Y, Bui J, Zellers CL, Yuan C, Babic A, Khalaf N, Aguirre A, Ng K, Miksad RA, Bullock AJ, Chang DT, Tseng JF, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar M, Wollison B, Laing A, Hahn WC, Meyerson M, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Wolpin BM. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2018 Mar 08; 4(3):e173420. PMID: 29098284.
- Published on 2/6/2018
de Geus SWL, Kasumova GG, Sachs TE, Ng SC, Kent TS, Moser AJ, Vahrmeijer AL, Callery MP, Tseng JF. Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic adenocarcinoma. HPB (Oxford). 2018 Feb 06. PMID: 29426635.
- Published on 12/1/2017
Klompmaker S, Zoggel DV, Watkins AA, Eskander MF, Tseng JF, Besselink MG, Moser AJ. Nationwide Evaluation of Patient Selection for Minimally Invasive Distal Pancreatectomy Using American College of Surgeons' National Quality Improvement Program. Ann Surg. 2017 Dec; 266(6):1055-1061. PMID: 27607097.
- Published on 10/5/2017
Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Bui JL, Yuan C, Qian ZR, Babic A, Da Silva A, Nowak JA, Khalaf N, Brais LK, Welch MW, Zellers CL, Ng K, Chang DT, Miksad RA, Bullock AJ, Tseng JF, Swanson RS, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Hornick JL, Ogino S, Fuchs CS, Hezel AF, Koong AC, Wolpin BM. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Br J Cancer. 2017 Dec 05; 117(12):1874-1882. PMID: 28982112.
- Published on 10/4/2017
de Geus SWL, Kasumova GG, Eskander MF, Ng SC, Kent TS, James Moser A, Vahrmeijer AL, Callery MP, Tseng JF. Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study. J Gastrointest Surg. 2018 Feb; 22(2):214-225. PMID: 29235000.
- Published on 10/1/2017
Struyvenberg MR, Fong ZV, Martin CR, Tseng JF, Clancy TE, Fernández-Del Castillo C, Tillman HJ, Bellin MD, Freedman SD. Impact of Treatments on Diabetic Control and Gastrointestinal Symptoms After Total Pancreatectomy. Pancreas. 2017 Oct; 46(9):1188-1195. PMID: 28902790.
- Published on 10/1/2017
Kasumova GG, Tabatabaie O, Najarian RM, Callery MP, Ng SC, Bullock AJ, Fisher RA, Tseng JF. Surgical Management of Gallbladder Cancer: Simple Versus Extended Cholecystectomy and the Role of Adjuvant Therapy. Ann Surg. 2017 Oct; 266(4):625-631. PMID: 28692469.
- Published on 7/14/2017
de Geus SWL, Eskander MF, Kasumova GG, Ng SC, Kent TS, Mancias JD, Callery MP, Mahadevan A, Tseng JF. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. Cancer. 2017 Nov 01; 123(21):4158-4167. PMID: 28708929.
View 125 more publications: View full profile at BUMC